A Biomarker-Driven Approach to Identify Pathogenic Mechanisms and Novel Therapeutic Targets in Chronic Wounds (Pyoderma Gangrenosum) using Tildrakizumab

Phase 2

Completed

• Conditions: Pyoderma Gangrenosum; Inflammatory and Immune System - Other inflammatory or immune system disorders; Skin - Dermatological conditions

• Registration Number: ACTRN12623000211662
• Lead Sponsor: iverpool Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-02-28
• Study Completion: 2023-08-10
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Age greater than or equal to 18 years
• A minimum of one (1) active ulcer of Pyoderma Gangrenosum as determined by the PI

Exclusion Criteria

Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
• Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic immunosuppressants (those with prior use of these medications must have conducted a washout period of 4 weeks or 5 half-lives of the drug, whichever is longer).
• Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data.
• Have received a vaccination with a live viral of bacterial component within 4 weeks or less of intended Tildrakizumab administration
• Patients not willing to abstain from receiving live vaccinations during treatment and for at least 17 weeks after treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified